Biofeedback Group for Malignancies

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
The University of Texas at Arlington, Arlington, TX
Malignancies+1 More
Glucose-based biofeedback - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This study aims to promote daily physical activity in cancer survivors who are at high risk for type 2 diabetes (T2D) by using a personalized biological-based feedback strategy. T2D is one of the most common co-occurring conditions in cancer survivors and can worsen cancer-related health outcomes, especially in those who are insufficiently active. The investigators hypothesize that seeing the immediate impacts of exercise on their biological status will motivate cancer survivors to exercise. The investigators will use real-time data from continuous glucose monitor to demonstrate the acute impact of physical activity and measure daily activity levels using wearable trackers. As wearable sensor technology is constantly advancing, this study is the first step to exploring how researchers can use wearable sensors to help people make a direct connection between their daily behaviors and health outcomes.

Eligible Conditions

  • Survival Rate (Survivorship)
  • Malignancies

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Through study completion, an average of 3 months.

Month 3
Changes in daily physical activity level
Feasibility of delivering personalized glucose-based feedback

Trial Safety

Trial Design

2 Treatment Groups

Standard Care Group
1 of 2
Biofeedback Group
1 of 2
Active Control
Experimental Treatment

50 Total Participants · 2 Treatment Groups

Primary Treatment: Biofeedback Group · No Placebo Group · N/A

Biofeedback GroupExperimental Group · 2 Interventions: Glucose-based biofeedback, Glucose monitoring · Intervention Types: Behavioral, Device
Standard Care Group
Behavioral
ActiveComparator Group · 1 Intervention: Standard feedback · Intervention Types: Behavioral
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Glucose monitoring
2019
N/A
~10

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 3 months.
Closest Location: The University of Texas at Arlington · Arlington, TX
2013First Recorded Clinical Trial
1 TrialsResearching Malignancies
1 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 9 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You must be 18 years or older to participate in this study.
You have had a diagnosis of cancer.
You have completed curative-intended treatment for at least 3 months (except hormone therapy or long-term maintenance chemotherapy).
You are at high-risk for type 2 diabetes based on the American Diabetes Association Type 2 Diabetes Risk Test.
You are able to participate in moderate-vigorous intensity unsupervised exercise.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.